Amy Emerson is the chief executive officer (CEO) of Lykos Therapeutics, a clinical-stage company dedicated to changing the way mental health conditions are treated. She became CEO when the company was formed in 2014 to take on the challenging task of bringing a psychedelic through the FDA regulatory pathway. She has led the company through its successful completion of six Phase 2 studies and two Phase 3 studies, fundraising of approximately $150 million and growing to over 120 employees. Amy has decades of pharmaceutical development and research experience and has brought products from Phase 1 studies through FDA approval. From 1993 to 2009, she worked in various fields including immunology, oncology and vaccines in roles with increasing levels of responsibility for companies such as Novartis and Chiron. Pursuing her love of science and nature, Amy earned her B.S. in Genetics and Cell Biology from Washington State University in 1992.